An Open-Label, Multicenter Study of the Effects of Remission Maintenance Therapy with Ceplene (Histamine Dihydrochloride), Given in Conjunction with Low-Dose Interleukin-2 (IL-2, Proleukin), on Immune Response and Minimal Residual Disease (MRD) in Adult Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1)

Trial Profile

An Open-Label, Multicenter Study of the Effects of Remission Maintenance Therapy with Ceplene (Histamine Dihydrochloride), Given in Conjunction with Low-Dose Interleukin-2 (IL-2, Proleukin), on Immune Response and Minimal Residual Disease (MRD) in Adult Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1)

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Histamine dihydrochloride (Primary) ; Interleukin-2
  • Indications Acute myeloid leukaemia
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms RE:MISSION
  • Sponsors Immune Pharmaceuticals Inc; Meda Pharma GmbH & Co KG
  • Most Recent Events

    • 09 Aug 2017 This trial has been discontinued in Belgium, as per European Clinical Trials Database record.
    • 05 Jul 2017 Results published in the Media Release
    • 05 Jul 2017 According to an Immune Pharmaceuticals Inc media release, results from this trial were published in the hematology journal, Leukemia, published by Springer Nature 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top